Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): study protocol for an adaptive randomized controlled trial

Jesse Ross, Rubeshan Perumal, Allison Wolf, Mbali Zulu, Kevin Guzman, Boitumelo Seepamore, Karl Reis, Hlengiwe Nyilana, Senzo Hlathi, Radhamoney Narasimmulu, Ying Kuen K. Cheung, K. Rivet Amico, Gerald Friedland, Amrita Daftary, Jennifer Zelnick, Kogieleum Naidoo, Max R. O’DonnellTrials 2023 · DOI

This paper presents the study protocol for the ADAP-TIV trial, a research project designed to tackle one of the most significant challenges in global health: ensuring medication adherence for patients facing the "syndemic" of multi-drug resistant tuberculosis (MDR-TB) and HIV.

TL;DR

The ADAP-TIV trial uses a Bayesian adaptive randomized design to evaluate four different strategies—ranging from digital mHealth tools to intensive psychosocial support—for improving treatment outcomes in South African patients with MDR-TB and HIV. By titrating the intensity of support based on individual patient needs, the study aims to identify the most effective way to deploy modern, all-oral drug regimens in high-burden settings.

What Problem Does This Paper Address?

While medical science has recently produced highly effective, all-oral treatment regimens for MDR-TB (like bedaquiline) and advanced antiretroviral therapy (ART) for HIV, these drugs only work if patients take them consistently. In South Africa, where over half of TB patients are co-infected with HIV, the treatment burden is immense.

Traditionally, TB programs relied on Directly Observed Therapy (DOT), where a healthcare worker physically watches a patient swallow their pills. This "one-size-fits-all" approach is often rigid, paternalistic, and difficult for patients to maintain over long periods. There is a critical gap in knowing how to transition to Differentiated Service Delivery (DSD)—a patient-centered model that tailors the level of support to the individual’s specific clinical and social needs.

Methods

The ADAP-TIV trial is a prospective, four-arm, adaptive randomized controlled trial (RCT).

The Four Arms:

  1. Enhanced Standard of Care: Usual clinic care plus extra treatment literacy training for staff.
  2. Psychosocial Support: Monthly counseling, adherence support groups, and home visits.
  3. mHealth: Use of the Wisepill RT3000, a cellular-enabled electronic pillbox that records every opening. Patients receive weekly SMS reminders and "rescue" calls if doses are missed.
  4. Combined Support: Both mHealth and psychosocial interventions.

Key Innovations:

  • Bayesian Adaptive Randomization: Unlike traditional RCTs with fixed 1:1 randomization, this trial uses a "run-in" period for the first 40 participants. After that, a Bayesian algorithm modifies the randomization weights to favor the arms that are showing better preliminary results. This is more ethical (more patients get the "better" treatment) and statistically efficient.
  • Titrated Support: Within each arm, the intensity of the intervention is not static. If a patient shows signs of struggling (e.g., low adherence scores or missed pillbox openings), the frequency of counseling or phone check-ins increases.

Datasets

As a study protocol, the paper describes the planned data collection rather than a completed dataset.

  • Target Population: 400 adult patients with confirmed MDR-TB and HIV.
  • Setting: Durban, South Africa (specifically the King Dinuzulu Hospital and KwaMashu community clinic).
  • Primary Outcome: A composite clinical endpoint at 12 months, including survival, negative TB culture, retention in care, and undetectable HIV viral load.

Key Insights and Ideas

  • The DSD Framework for TB: The study represents a major shift from "watching the patient" to "supporting the patient." It applies the DSD framework—already successful in HIV care—to the more complex MDR-TB/HIV co-infection cascade.
  • Electronic Dose Monitoring (EDM) as a Proxy: By using the Wisepill device, researchers can treat "pillbox opening" as a real-time surrogate for adherence. This allows for immediate intervention before a patient's viral load rises or their TB culture reverts to positive.
  • Addressing the "Syndemic": The trial recognizes that TB and HIV cannot be treated in silos. The primary outcome is a "composite success" measure, acknowledging that a patient is only truly healthy if both infections are managed simultaneously.

Key Results

As this is a protocol paper, quantitative results are not yet available. However, the authors provide a detailed Power Analysis (Table 3).

  • The study is powered to detect a superior arm with a probability (power) ranging from 74% to 98%, depending on the actual success rates of the interventions (estimated between 70% and 90%).
  • The trial began recruitment in March 2023, with an estimated completion date in March 2027.

Limitations and Future Work

  • Cost of Technology: The Wisepill devices cost approximately $100 each. While the authors argue that preventing treatment failure is more cost-effective in the long run, the initial price point may be a barrier for scale-up in low-income countries.
  • Generalizability: The trial is centered in KwaZulu-Natal, the global epicenter of the TB/HIV epidemic. While the results will be highly relevant to Southern Africa, they may not perfectly translate to regions with different cultural or structural barriers to care (e.g., Southeast Asia).
  • Refractory Barriers: The authors acknowledge that some patients face "deep-seated" behavioral or structural challenges (like extreme poverty or severe stigma) that even intensive psychosocial or digital support may not fully overcome. Future work will likely involve a cost-effectiveness analysis to see which "titrated" model offers the best value for public health systems.

Summary updated

Abstract

ClinicalTrials.gov NCT05633056. Registered on 1 December 2022.
BibTeX
@inproceedings{ross2023adaptive,
  author = {Jesse Ross and Rubeshan Perumal and Allison Wolf and Mbali Zulu and Kevin Guzman and Boitumelo Seepamore and Karl Reis and Hlengiwe Nyilana and Senzo Hlathi and Radhamoney Narasimmulu and Ying Kuen K. Cheung and K. Rivet Amico and Gerald Friedland and Amrita Daftary and Jennifer Zelnick and Kogieleum Naidoo and Max R. O’Donnell},
  title = {{Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): study protocol for an adaptive randomized controlled trial}},
  booktitle = {Trials},
  year = {2023},
  doi = {10.1186/s13063-023-07520-9},
}
Figure